Previous 10 | Next 10 |
In his book “Super Stocks” published nearly 40 years ago, Ken Fisher described an investing philosophy about high growth companies, trading at a discount. The philosophy combines elements of high growth and value, including both quantitative and qualitative factors. ...
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
Ironwood Pharmaceuticals (NASDAQ:IRWD) rose 1.4% after speculation the company could be a takeout candidate after hiring a CFO with M&A experience. Ironwood's hiring of Sravan Emany may be noteworthy as he was chief strategy officer at Integra LifeSciences and previously wa...
Ironwood (NASDAQ:IRWD) has appointed Sravan Emany as senior vice president, CFO, effective December 6. He will report to Thomas McCourt, chief executive officer of Ironwood. Most recently, Mr. Emany served as corporate vice president, commercial excellence and chief strate...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood’s Leadership Team and be responsible for all financ...
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2021 Results Conference Call November 04, 2021 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Jason Rickard - Chief Operating Officer Conference...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Ironwood Pharmaceuticals, inc (NASDAQ: IRWD) Q3 2021 Earnings Call Nov 4, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals, inc (IRWD) Q3 2021 Earnings Call Tra...
Ironwood Pharmaceuticals (NASDAQ:IRWD) has entered into a collaboration and license option agreement with COUR Pharmaceutical Development Company, a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The agreement gives Ironwood an option ...
Ironwood Pharmaceuticals (NASDAQ:IRWD): Q3 Non-GAAP EPS of $0.33 beats by $0.01; GAAP EPS of $0.34 beats by $0.03. Revenue of $103.74M (+0.3% Y/Y) misses by $1.53M. Press Release For further details see: Ironwood Pharmaceuticals EPS beats by $0.01, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...